已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial

医学 妇女健康倡议 醋酸甲孕酮 危险系数 随机对照试验 安慰剂 激素疗法 妇科 子宫内膜癌 不利影响 冲程(发动机) 激素替代疗法(女性对男性) 内科学 乳腺癌 雌激素 观察研究 置信区间 癌症 机械工程 替代医学 病理 工程类 睾酮(贴片)
作者
Jacques E. Rossouw,Garnet L. Anderson,Ross L. Prentice,Andrea Z. LaCroix,Charles Kooperberg,Marcia L. Stefanick,Rebecca D. Jackson,Shirley A.A. Beresford,Barbara V. Howard,Karen Johnson,Jane Morley Kotchen,Judith K. Ockene
出处
期刊:JAMA [American Medical Association]
卷期号:288 (3): 321-333 被引量:15211
标识
DOI:10.1001/jama.288.3.321
摘要

ContextDespite decades of accumulated observational evidence, the balance of risks and benefits for hormone use in healthy postmenopausal women remains uncertain.ObjectiveTo assess the major health benefits and risks of the most commonly used combined hormone preparation in the United States.DesignEstrogen plus progestin component of the Women's Health Initiative, a randomized controlled primary prevention trial (planned duration, 8.5 years) in which 16608 postmenopausal women aged 50-79 years with an intact uterus at baseline were recruited by 40 US clinical centers in 1993-1998.InterventionsParticipants received conjugated equine estrogens, 0.625 mg/d, plus medroxyprogesterone acetate, 2.5 mg/d, in 1 tablet (n = 8506) or placebo (n = 8102).Main Outcomes MeasuresThe primary outcome was coronary heart disease (CHD) (nonfatal myocardial infarction and CHD death), with invasive breast cancer as the primary adverse outcome. A global index summarizing the balance of risks and benefits included the 2 primary outcomes plus stroke, pulmonary embolism (PE), endometrial cancer, colorectal cancer, hip fracture, and death due to other causes.ResultsOn May 31, 2002, after a mean of 5.2 years of follow-up, the data and safety monitoring board recommended stopping the trial of estrogen plus progestin vs placebo because the test statistic for invasive breast cancer exceeded the stopping boundary for this adverse effect and the global index statistic supported risks exceeding benefits. This report includes data on the major clinical outcomes through April 30, 2002. Estimated hazard ratios (HRs) (nominal 95% confidence intervals [CIs]) were as follows: CHD, 1.29 (1.02-1.63) with 286 cases; breast cancer, 1.26 (1.00-1.59) with 290 cases; stroke, 1.41 (1.07-1.85) with 212 cases; PE, 2.13 (1.39-3.25) with 101 cases; colorectal cancer, 0.63 (0.43-0.92) with 112 cases; endometrial cancer, 0.83 (0.47-1.47) with 47 cases; hip fracture, 0.66 (0.45-0.98) with 106 cases; and death due to other causes, 0.92 (0.74-1.14) with 331 cases. Corresponding HRs (nominal 95% CIs) for composite outcomes were 1.22 (1.09-1.36) for total cardiovascular disease (arterial and venous disease), 1.03 (0.90-1.17) for total cancer, 0.76 (0.69-0.85) for combined fractures, 0.98 (0.82-1.18) for total mortality, and 1.15 (1.03-1.28) for the global index. Absolute excess risks per 10 000 person-years attributable to estrogen plus progestin were 7 more CHD events, 8 more strokes, 8 more PEs, and 8 more invasive breast cancers, while absolute risk reductions per 10 000 person-years were 6 fewer colorectal cancers and 5 fewer hip fractures. The absolute excess risk of events included in the global index was 19 per 10 000 person-years.ConclusionsOverall health risks exceeded benefits from use of combined estrogen plus progestin for an average 5.2-year follow-up among healthy postmenopausal US women. All-cause mortality was not affected during the trial. The risk-benefit profile found in this trial is not consistent with the requirements for a viable intervention for primary prevention of chronic diseases, and the results indicate that this regimen should not be initiated or continued for primary prevention of CHD.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
昵昵昵昵呀完成签到,获得积分20
刚刚
维时完成签到,获得积分10
刚刚
刚刚
田様应助静汉采纳,获得10
7秒前
玩儿完成签到,获得积分10
8秒前
隐形曼青应助chrissylaiiii采纳,获得10
8秒前
9秒前
逯逯逯发布了新的文献求助10
12秒前
dj发布了新的文献求助10
13秒前
传奇3应助于某人采纳,获得10
13秒前
14秒前
田様应助小琦琦采纳,获得10
15秒前
852应助king采纳,获得10
16秒前
维时发布了新的文献求助10
17秒前
chenshiyi185完成签到,获得积分20
17秒前
18秒前
19秒前
五六七发布了新的文献求助10
20秒前
龚仕杰完成签到 ,获得积分10
21秒前
21秒前
dj完成签到 ,获得积分10
22秒前
所所应助lily88采纳,获得10
26秒前
27秒前
27秒前
20224273完成签到 ,获得积分20
28秒前
Evelyn完成签到 ,获得积分10
28秒前
Going发布了新的文献求助10
31秒前
InfoNinja应助闪闪的傲蕾采纳,获得30
31秒前
32秒前
MRJ发布了新的文献求助10
32秒前
33秒前
33秒前
冷傲的咖啡豆完成签到 ,获得积分10
34秒前
37秒前
上进生完成签到,获得积分10
38秒前
五香完成签到 ,获得积分10
38秒前
舒适逊发布了新的文献求助10
38秒前
39秒前
闪闪的傲蕾完成签到,获得积分20
42秒前
上进生发布了新的文献求助10
42秒前
高分求助中
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
юрские динозавры восточного забайкалья 800
English Wealden Fossils 700
Chen Hansheng: China’s Last Romantic Revolutionary 500
宽禁带半导体紫外光电探测器 388
COSMETIC DERMATOLOGY & SKINCARE PRACTICE 388
Pearson Edxecel IGCSE English Language B 300
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3142306
求助须知:如何正确求助?哪些是违规求助? 2793200
关于积分的说明 7805956
捐赠科研通 2449516
什么是DOI,文献DOI怎么找? 1303345
科研通“疑难数据库(出版商)”最低求助积分说明 626823
版权声明 601300